Objective . To improve the treatment of tumors

we studied the combined effects of docetaxel and batimastat （BB 94） on mouse forestomach carcinoma （MFC）

and compared them with doxorubicin. Methods and results. In vitro

growth curve analysis

MTT assay and clonogenic assay used to determine the cytotoxic effect of docetaxel or/and BB 94 on MFC cell showed that docetaxel but not BB 94 had a significant cytotoxicity

and the effect of docetaxel wasn’t enhanced by BB 94. In early stage MFC tumor model

obvious antitumor effect of docetaxel or doxorubicin given i.v. at maximum tolerated dose （MTD

docetaxel: 20mg/kg; doxorubicin: 6mg/kg） every 4 days for 3 injections （q4d×3）

even that of BB 94 （30mg/kg i.p. qd×20） was observed. Tumor growth inhibition was greater for docetaxel batimastat （96.0%） than for doxorubicin-batimastat （88.0%）

docetaxel （89.0%）

doxorubicin （68.0%） and BB 94 （33.0%）

and the effect of docetaxel could be potentiated by BB 94. Docetaxel also showed activity against advanced stage MFC tumor in dose-dependent manner

and was more effective at MTD than doxorubicin with 4/5 regressions

46.5 days tumor growth delay and 2.8log10 tumor cell kill. Conclusion. Our results suggest that in the MFC model with dose and schedule used

docetaxel is an effective cytotoxic new drug against MFC tumor and BB 94 enchances the antitumor activity of docetaxel.